Genzyme a SANOFI Company
II - In-house lobbyists and trade/business/professional associations
Companies & groups
Kendall Street, 500
Cambridge MA 02142
(+1) 617 252 7500
rue de la science 14
Mr David Meeker
Ms Vinciane Pirard
Sr Director Public Affairs
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
rare disease policies, pharmaceutical dossiers and use of biotechnology in health care
in particular in the context of and related to:
- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products
- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
- EU Net HTA Joint action
- EUCERD Joint Action
Expert Group on Rare diseases
To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.
50%: 1 25%: 2
|No accredited persons|
Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)
01/2014 - 12/2014
400,000 € - 499,999 €
No funding received from the EU institutions during the last closed financial year.
By its registration the organisation has signed the Transparency Register Code of Conduct.